Phase I/II clinical trial to evaluate the efficacy and safety of DFP-17729 in patients with unresectable/recurrent/progressive pancreatic cancer
Phase 1
- Conditions
- Patients with unresectable/recurrent/progressive pancreatic cancer
- Registration Number
- JPRN-UMIN000042064
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Not provided
Exclusion Criteria
Patient without 1)Obvious infection 2)Severe heart diseases 3)Severe complicatios 4)Brain metasitases 5)Severe digestive diseases 6)Severe thromboembolisms 7)Severe diarrhea 8)Severe psychosis 9)Double cancer 10)Pregnant woman/ Breastfeeding 11)Continuous systemic administration of steroids 12)Effects of pretreatment 13)Blood transfusion and blood component preparation 14)Patients judged to be inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method